Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 364

Sort by

Sort Order Select

Journal Articles

E2A-PBX1 functions as a coactivator for RUNX1 in acute lymphoblastic leukemia

Wen-Chieh Pi, Jun Wang, Miho Shimada, Jia-Wei Lin, Huimin Geng, Yu-Ling Lee, Rui Lu, Dongxu Li, Gang Greg Wang, Robert G. Roeder, Wei-Yi Chen

Blood (2020) 136 (1): 11–23.

https://doi.org/10.1182/blood.2019003312

Published: 2020

Includes: Supplemental data

Journal Articles

Co-Expression of SYK and ZAP70 Subverts Negative B-Cell Selection and Enables Oncogenic Signaling in Multiple B-Cell Malignancies

Teresa Sadras, PhD, Mickaël Martin, MD PhD, Lauren Kim-Sing, Jevon Cutler, PhD, Gal Lenz, PhD, Anne Marie Knapp, Dana Ghergus, MD PhD, Fabien Delmotte, Cédric Schleiss, Anne-Sophie Korganow, MD PhD, Pauline Soulas-Sprauel, PharmD, PhD, Zhengshan Chen, MD PhD, Akhilesh Pandey, MD PhD, David M. Weinstock, MD, Hassan Jumaa, PhD, Eric Meffre, PhD, Thierry Martin, MD PhD, Markus Müschen, MD PhD

Blood (2019) 134 (Supplement_1): 295.

https://doi.org/10.1182/blood-2019-128999

Published: 2019

Journal Articles

Spontaneous Remission of Secondary Acute Lymphoblastic Leukemia Associated with Lenalidomide Therapy for Multiple Myeloma

Arjun Lakshman, MBBS, Cai Chen, Kayla Parr, Sarah McGregor, Sara Monaghan, MD, Steven H. Swerdlow, MD, Warren D Shlomchik, MD, Mounzer Agha, MD, Sawa Ito, MD PhD

Blood (2019) 134 (Supplement_1): 5200.

https://doi.org/10.1182/blood-2019-129257

Published: 2019

Journal Articles

The Paracaspase MALT1 Acts Independently of Pre-B-Cell Receptor Signaling As a Key Factor in Leukemic Cell Survival in Precursor B-Cell Acute Lymphoblastic Leukemia

Nakhle S. Saba, MD, Jade Meyers, Lorena Fontan, PhD, Ari Melnick, MD, Adrian Wiestner, MD PhD, Patricia Lobelle-Rich, Ekaterina Kim, MS, Jan A. Burger, MD PhD, Yara Mouawad, MD, Prescott L. Deininger, PhD, Francisco Socola, MD, Hana Safah, MD, Erik K Flemington, PhD

Blood (2019) 134 (Supplement_1): 1288.

https://doi.org/10.1182/blood-2019-131376

Published: 2019

Journal Articles

Phase 1 Study of on Site Manufactured Anti-CD19 CAR-T Cells: Responses in Subjects with Rapidly Progressive Refractory Lymphomas

Blood (2019) 134 (Supplement_1): 4074.

https://doi.org/10.1182/blood-2019-131300

Published: 2019

Journal Articles

Transcriptomic Profile of Bone Marrow-Derived Mesenchymal Stromal Cells of Pediatric Pre-B Acute Lymphoblastic Leukemia Patients and Healthy Donors after Interaction with Leukemic Cells

Tuba Özdemi̇r Sanci, MSc, Hilal Özdağ, PhD, Yasin Köksal, MSc, Seda Tasır Yılmaz, MSc, Husniye Nese Yarali, MD, Namik Yasar Özbek, MD, Habibe Meltem Özgüner, MD

Blood (2019) 134 (Supplement_1): 3957.

https://doi.org/10.1182/blood-2019-128282

Published: 2019

Journal Articles

Targeting Unique Synthetic Lethal Interactions between PI3K and MYC in B-ALL

Gang Xiao, PhD, Kohei Kume, PhD, Huimin Geng, PhD, Than Than Han, MS, Lars Klemm, MS, Markus Müschen, MD PhD

Blood (2019) 134 (Supplement_1): 3785.

https://doi.org/10.1182/blood-2019-128719

Published: 2019

Journal Articles

Ifitm3 Is Essential for PI(3,4,5)P3-Dependent B-Cell Activation and Leukemogenesis

Jaewoong Lee, PhD, Gang Xiao, PhD, Kadriye Nehir Nehir Cosgun, PhD, Huimin Geng, PhD, Ning Ma, PhD, Lai N Chan, PhD, Kohei Kume, PhD, Matthew Nix, PhD, Zhengshan Chen, MD PhD, Chun-Wei David Chen, PhD, Jianjun Chen, PhD, Vishal Khairnar, PhD, Arun P. Wiita, MD PhD, Andrei Thomas-Tikhonenko, PhD, Michael Farzan, MD PhD, Michael S. Diamond, PhD, Jae U Jung, PhD, Nagarajan Vaidehi, PhD, Markus Müschen, MD PhD

Blood (2019) 134 (Supplement_1): 2782.

https://doi.org/10.1182/blood-2019-127615

Published: 2019

Journal Articles

Impact of Targeted Immunotherapies and Novel Cytogenetic and Clinical Risk Groups on Outcome after Allogeneic Hematopoietic Stem Cell Transplant (AlloHCT) for Acute Lymphoblastic Leukemia (ALL): The Mayo Clinic Cohort

Zaid Abdel Rahman, MD, Michael G. Heckman, Kevin C. Miller, BS, Patricia Greipp, DO, Matthew R Spiegel, Sharad Khurana, MDMSc, Hassan B. Alkhateeb, MD, Mrinal M Patnaik, MDMBBS, Lisa Z. Sproat, MD, Liuyan Jiang, Vivek Roy, MD, Mark Litzow, MD, Mohamed A Kharfan-Dabaja, MDMBA, William J Hogan, MB, BCh, James M. Foran, MD

Blood (2019) 134 (Supplement_1): 2588.

https://doi.org/10.1182/blood-2019-122068

Published: 2019

Journal Articles

Phase I Trial of Ibrutinib, Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Sikander Ailawadhi, MD, Aneel Paulus, MD, Victoria R. Alegria, Betsy Laplant, MS, Muhamad Alhaj Moustafa, MD, Dustin Chapin, Keisha Jackson, Prachi Jani, MD, Salman Ahmed, MD, Brett Edwards, Alak Manna, PhD, Vivek Roy, MD, Taimur Sher, MD, Asher A. Chanan-Khan, MD

Blood (2019) 134 (Supplement_1): 1912.

https://doi.org/10.1182/blood-2019-128233

Published: 2019

Journal Articles

Yet another susceptibility variant for ALL: what’s next?

Kjeld Schmiegelow

Blood (2019) 133 (7): 628–629.

https://doi.org/10.1182/blood-2018-12-891564

Published: 2019

Journal Articles

Acquired Resistance to BRAF Inhibition in Hcl Is Rare and Retreatment with Vemurafenib at Relapse Can Induce High Response Rates: Final Results of a Phase II Trial of Vemurafenib in Relapsed Hcl

Jae H. Park, MD, Jeong-Ok Lee, MD, Richard M. Stone, MD, Alan Saven, MD, Jessica K. Altman, MD, Michael R. Grever, MD, Kanti R Rai, MD, Shreya Vemuri, Omar I Abdel-Wahab, MD, Martin S. Tallman, MD

Blood (2018) 132 (Supplement 1): 392.

https://doi.org/10.1182/blood-2018-99-119949

Published: 2018

Journal Articles

Cooperation between SYK and ZAP70 Kinases As a Driver of Oncogenic BCR-Signaling in B-Cell Malignancies

Teresa Sadras, PhD, Jevon Cutler, Julia Aguade-Gorgorio, PhD, Zhengshan Chen, MD PhD, Kadriye Nehir Cosgun, PhD, Akhilesh Pandey, MD PhD, Markus Muschen, MD

Blood (2018) 132 (Supplement 1): 3922.

https://doi.org/10.1182/blood-2018-99-116954

Published: 2018

Journal Articles

Piggybac CD19 CAR T Cells Eradicate CNS Leukemia By Direct Delivery into Cerebral Ventricle of Xenograft Mice Model

Kuniaki Tanaka, MD, Itaru Kato, MD, PhD, Miyuki Tanaka, MD, PhD, Daisuke Morita, MD, PhD, Yoshiyuki Takahashi, MD, PhD, Tatsutoshi Nakahata, MD, PhD, Katsutsugu Umeda, MD, PhD, Hidefumi Hiramatsu, MD, PhD, Souichi Adachi, MD PhD, Junko Takita, MD, PhD, Yozo Nakazawa, MD, PhD

Blood (2018) 132 (Supplement 1): 4028.

https://doi.org/10.1182/blood-2018-99-111733

Published: 2018

Journal Articles

Amsacrine, Etoposide and Methylprednisolone As Part of the Therapy Intensification in Children with Acute Lymphoblastic Leukemia: A Retrospective Analysis in the Trial Coall 08-09

Gabriele Escherich, Katharina Wos, MD, Franziska Schramm, MD, Martin A. Horstmann, MD

Blood (2018) 132 (Supplement 1): 5168.

https://doi.org/10.1182/blood-2018-99-112623

Published: 2018

Journal Articles

Importance of Detection of Intracellular Myeloperoxidase, CD13, CD79a, CD22, CD3 and Terminal Deoxynucleotidyl Transferase By Flow Cytometry Diagnosis of Acute Leukemias

Aldair Sousa Paiva, PhD, Hugo Diogenes De Oliveira Paiva, MD, Geraldo Barroso Cavalcanti, Jr., PhD, Frank Bahia, MD, Rodrigo Villar Freitas, MD, Lenilton Silva Silveira, Jr., MD, Lorena KF Silva, Roberto C Vasconcelos, MD, Dany GKC Silva, Victor lima Soares, Erica Aires Gil, MD, Geisa Januario, Maria Fernandes, PhD, Alessandra Suelen Jardim

Blood (2018) 132 (Supplement 1): 5194.

https://doi.org/10.1182/blood-2018-99-118880

Published: 2018

Journal Articles

Lgr5 Enables Positive B-Cell Selection and Tumor-Initiation in B-Cell Malignancies

Kadriye Nehir Cosgun, PhD, Gauri Deb, MS, PhD, Xin Yang, MD, Gang Xiao, PhD, Teresa Sadras, PhD, Franziska Auer, PhD, Jaewoong Lee, PhD, Anthony Abarientos, BSc, Maurizio Mangolini, PhD, Ali Aghajanirefah, PhD, Huimin Geng, PhD, Hassan Jumaa, PhD, Andrew G. Polson, PhD, Hans Clevers, MD PhD, Markus Muschen, MD

Blood (2018) 132 (Supplement 1): 547.

https://doi.org/10.1182/blood-2018-99-116956

Published: 2018

Journal Articles

Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Combination with Azacitidine or Daratumumab in Non-APL Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Rachel J. Cook, MD, Tamara Moyo, MD PhD, Jane L. Liesveld, MD, David A. Rizzieri, MD, Eytan M. Stein, MD, Stephane De Botton, MD PhD, Gail J. Roboz, MD, Mikkael A. Sekeres, MD MS, Joseph G. Jurcic, MD, Azra Raza, MD, Robert L. Redner, MD, Dale L. Bixby, MD PhD, Jorge E. Cortes, MD, Kristin Stephens, Angela Volkert, Qing Kang, PhD, Emmanuelle Di Tomaso, PhD, David A. Roth, MD, Carlos E Vigil, MD

Blood (2018) 132 (Supplement 1): 2735.

https://doi.org/10.1182/blood-2018-99-111285

Published: 2018

Journal Articles

Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study

Blood (2018) 132 (Supplement 1): 36.

https://doi.org/10.1182/blood-2018-99-114955

Published: 2018

Journal Articles

Blinatumomab in Combination with Immune Checkpoint Inhibitors of PD-1 and CTLA-4 in Adult Patients with Relapsed/Refractory (R/R) CD19 Positive B-Cell Acute Lymphoblastic Leukemia (ALL): Preliminary Results of a Phase I Study

Jonathan Webster, MD, Marlise R. Luskin, MD, Gabrielle T. Prince, MD, Amy E. DeZern, MD, Daniel J. DeAngelo, MD, Mark J. Levis, MD, Amanda Blackford, Elad Sharon, MD MPH, Howard Streicher, MD, Leo Luznik, MD, Ivana Gojo, MD

Blood (2018) 132 (Supplement 1): 557.

https://doi.org/10.1182/blood-2018-99-111845

Published: 2018

NARROW

E2A-PBX1 functions as a coactivator for RUNX1 in acute lymphoblastic leukemia

Co-Expression of SYK and ZAP70 Subverts Negative B-Cell Selection and Enables Oncogenic Signaling in Multiple B-Cell Malignancies

Spontaneous Remission of Secondary Acute Lymphoblastic Leukemia Associated with Lenalidomide Therapy for Multiple Myeloma

The Paracaspase MALT1 Acts Independently of Pre-B-Cell Receptor Signaling As a Key Factor in Leukemic Cell Survival in Precursor B-Cell Acute Lymphoblastic Leukemia

Phase 1 Study of on Site Manufactured Anti-CD19 CAR-T Cells: Responses in Subjects with Rapidly Progressive Refractory Lymphomas

Transcriptomic Profile of Bone Marrow-Derived Mesenchymal Stromal Cells of Pediatric Pre-B Acute Lymphoblastic Leukemia Patients and Healthy Donors after Interaction with Leukemic Cells

Targeting Unique Synthetic Lethal Interactions between PI3K and MYC in B-ALL

Ifitm3 Is Essential for PI(3,4,5)P3-Dependent B-Cell Activation and Leukemogenesis

Impact of Targeted Immunotherapies and Novel Cytogenetic and Clinical Risk Groups on Outcome after Allogeneic Hematopoietic Stem Cell Transplant (AlloHCT) for Acute Lymphoblastic Leukemia (ALL): The Mayo Clinic Cohort

Phase I Trial of Ibrutinib, Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Yet another susceptibility variant for ALL: what’s next?

Acquired Resistance to BRAF Inhibition in Hcl Is Rare and Retreatment with Vemurafenib at Relapse Can Induce High Response Rates: Final Results of a Phase II Trial of Vemurafenib in Relapsed Hcl

Cooperation between SYK and ZAP70 Kinases As a Driver of Oncogenic BCR-Signaling in B-Cell Malignancies

Piggybac CD19 CAR T Cells Eradicate CNS Leukemia By Direct Delivery into Cerebral Ventricle of Xenograft Mice Model

Amsacrine, Etoposide and Methylprednisolone As Part of the Therapy Intensification in Children with Acute Lymphoblastic Leukemia: A Retrospective Analysis in the Trial Coall 08-09

Importance of Detection of Intracellular Myeloperoxidase, CD13, CD79a, CD22, CD3 and Terminal Deoxynucleotidyl Transferase By Flow Cytometry Diagnosis of Acute Leukemias

Lgr5 Enables Positive B-Cell Selection and Tumor-Initiation in B-Cell Malignancies

Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Combination with Azacitidine or Daratumumab in Non-APL Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study

Blinatumomab in Combination with Immune Checkpoint Inhibitors of PD-1 and CTLA-4 in Adult Patients with Relapsed/Refractory (R/R) CD19 Positive B-Cell Acute Lymphoblastic Leukemia (ALL): Preliminary Results of a Phase I Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only